Chronic spontaneous urticaria (CSU) is responsible for 80% of all cases of chronic hives, but 90% of people never know what ...

Jasper Therapeutics has reported complete responses in 10 of the 12 chronic hives patients who received the high dose of its ...

KIT antibody has shown promise in a Phase 1b/2a test in people with certain irritable skin conditions, sending its shares ...

Celldex Therapeutics reported Wednesday that its experimental medicine for a condition that causes chronic hives reduced hive activity in patients, completely clearing it in some. However ...

REDWOOD CITY, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company ...

Celldex Therapeutics (CLDX) is a clinical-stage biotechnology company that focuses on developing targeted therapies for rare ...

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...

In spite of treatment advances, chronic urticaria continues to impair patients' health-related quality of life (HRQoL) and drive up direct and indirect healthcare costs. As early as 1997 ...

Harris has seasonal allergies and urticaria, which are chronic hives as a result of allergies. She typically manages her ...

Jasper Therapeutics, a biotech looking to make stem cell transplants less taxing and to treat immune-mediated diseases, ...

AMSTERDAM — Patients with chronic spontaneous urticaria (CSU) experienced early and sustained improvements in symptom scores on treatment with barzolvolimab, during the 52-week follow-up of an ...